Melphalan
Links shared publicly online about this topic
Oncology Medical News about Multiple Myeloma Melphalan
mdlinx.com — “Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III Vista trial” View full resource at mdlinx.com
Most Recently Shared on April 22, 2010 at 7:59 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated m... http://bit.ly/aypjJQ #oncology
Melphalan and prednisone versus melphalan, prednis... [Leukemia. 2011] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on January 15, 2011 at 3:24 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Meta-analysis of trials comparing MPT to MP shows that MPT is superior therapy for transplant-ineligible patients (http://bit.ly/fE72YB).
ingentaconnect Melphalan/sorafenib interaction: Regional squamous cell carcinoma...
ingentaconnect.com — “ingentaconnect Melphalan/sorafenib interaction: Regional squamous cell carcinoma...” View full resource at ingentaconnect.com
Most Recently Shared on April 13, 2011 at 5:09 am By:
Melphalan/sorafenib interaction: Regional squamous cell carcinoma in an elderly patient: case report: (Source: R... http://bit.ly/eE4PR2
Oncology Medical News about Multiple Myeloma Thalidomide Melphalan
mdlinx.com — “Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study” View full resource at mdlinx.com
Most Recently Shared on June 4, 2010 at 7:57 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with n... http://bit.ly/cAvn6i #oncology
Oncology Medical Article | Thalidomide and Dexamethasone Versus Bortezomib and Dexamethasone for Melphalan Refractory Myeloma: A Randomized Study
mdlinx.com — “Oncology Medical Article: Thalidomide and Dexamethasone Versus Bortezomib and Dexamethasone for Melphalan Refractory Myeloma: A Randomized Study” View full resource at mdlinx.com
Most Recently Shared on March 15, 2012 at 10:07 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Thalidomide and Dexamethasone Versus Bortezomib and Dexamethasone for Melphalan Refractory Myeloma: A ... http://t.co/vduK1PE3 #oncology
High-Dose Melphalan Granted Orphan Drug Status for Neuroendocrine Liver Metastases
urlborg.com — “: The FDA has approved orphan drug designation for melphalan infusion in the treatment of patients with neuroendocrine tumors metastatic to the liver.” View full resource at urlborg.com
Most Recently Shared on June 10, 2009 at 4:49 pm By:
Medscape Oncology Oncology and Health Site
#Oncology High-Dose Melphalan Granted Orphan Drug Status for Neuroendocrine Liver Metastases http://ub0.cc/8g/0g
Percutaneous hepatic perfusion with melphalan improved hepatic PFS in ocular, cutaneous melanoma | HemOncToday
hemonctoday.com — “Percutaneous hepatic perfusion with melphalan improved hepatic PFS in ocular, cutaneous melanoma | HemOncToday” View full resource at hemonctoday.com
Most Recently Shared on June 5, 2010 at 9:46 pm By:
HemOnc Today Oncology and Health News
Percutaneous hepatic perfusion with melphalan improved hepatic PFS in ocular, cutaneous melanoma http://ht.ly/1Uzt5 #ASCO2010
Infusional mitoxantrone plus bolus melphalan as a ... [Cancer Invest. 2011] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on February 18, 2011 at 11:53 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Melphalan + mitoxantrone may be a good preparative regimen prior to stem cell transplantation (http://bit.ly/eOfIvq).
Effect of thalidomide with melphalan and prednison... [Ann Hematol. 2011] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on April 8, 2011 at 4:18 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Thalidomide added to melphalan and prednisone increases toxicity but doesn't negatively impact quality of life (http://1.usa.gov/fHdwYM).
Generation of a predictive melphalan resistance in... [PLoS One. 2011] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on May 12, 2011 at 2:11 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Researchers generate signature for melphalan sensitivity/resistance (http://1.usa.gov/iyDR3Q). Could optimize use of stem cell transplant?
Paper: Outcome of High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplant In Myeloma Associated with AL Amyloidosis
ash.confex.com — “Paper: Outcome of High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplant In Myeloma Associated with AL Amyloidosis” View full resource at ash.confex.com
Most Recently Shared on November 25, 2010 at 4:12 am By:
Robert Z. Orlowski Physician, Doctor, and Internist
Patients with myeloma and AL amyloidosis do as well with stem cell transplant as patients with myeloma only (http://bit.ly/eqsztk).
Paper: High Dose Melphalan with Autologous Stem Cell Transplantation Overcomes Poor Prognosis of Primary Amyloidosis
ash.confex.com — “Paper: High Dose Melphalan with Autologous Stem Cell Transplantation Overcomes Poor Prognosis of Primary Amyloidosis” View full resource at ash.confex.com
Most Recently Shared on November 25, 2010 at 4:14 am By:
Robert Z. Orlowski Physician, Doctor, and Internist
MD Anderson data: Outcome of patients with primary systemic AL amyloidosis was durable with stem cell transplant (http://bit.ly/fDCBm6).
Busulfan-Melphalan Superior as Myeloablative Tx for High-Risk Neuroblastoma : IMNG Oncology Digital Network
imngoncology.com — “IMNG Oncology is the leading source of news, views and original research and review articles that matter to the way office-based physicians practice oncology. Community Oncology, The Oncology Report and The Journal of Supportive Oncology address the continuum of cancer care for the busy clinical oncologist. Notable features include How We Do It, Supportive Insights, Community Translations, In the Pipeline, What Matters, What Your Patients Will Be Asking About, and iOncologist. Content addresses ” View full resource at imngoncology.com
Most Recently Shared on June 17, 2011 at 4:14 pm By:
Bob Finn - Medical News Net Health News
Do you treat kids with high-risk neuroblastoma? #ASCO11 study shows BUMEL is a superior regimen http://bit.ly/iEgwFj
Thalidomide and Dexamethasone Versus Bortezomib and Dexamethasone for Melphalan Refractory Myeloma: A Randomized Study - Hjorth - European Journal of Haematology - Wiley Online Library
www3.interscience.wiley.com — “Thalidomide and Dexamethasone Versus Bortezomib and Dexamethasone for Melphalan Refractory Myeloma: A Randomized Study - Hjorth - European Journal of Haematology - Wiley Online Library” View full resource at www3.interscience.wiley.com
Most Recently Shared on March 11, 2012 at 12:39 am By:
Depression Wisdom Active Health Library and OW Health
Thalidomide and Dexamethasone Versus Bortezomib and Dexamethasone for Melphalan Refractory Myeloma: A Randomized... http://t.co/Pz5C1QLh
VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function - OncologySTAT
oncologystat.com — “J Clin Oncol. 2009 Oct 26; Epub ahead of print - Cohort analysis of VISTA showed that VMP was superior to MP in efficacy and reversed renal impairment in 44% of patients.” View full resource at oncologystat.com
Most Recently Shared on November 18, 2009 at 4:46 pm By:
OncologySTAT Health Site and Oncology
Featured Journal Scan of the Week: VMP Is Effective in MM and Reverses Moderate Renal Impairment http://tinyurl.com/ydatlek
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Robert Z. Orlowski
Director of Myeloma Section at M. D. Anderson Cancer Center; Translational researcher who hates myeloma
-
Skin Cancer OW
Organizing skin cancer resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
